NS 398

Drug Profile

NS 398

Alternative Names: NS-398

Latest Information Update: 07 Aug 2007

Price : $50

At a glance

  • Originator Cayman Chemical; Taisho Pharmaceutical
  • Developer Taisho Pharmaceutical
  • Class Antipyretics; Nitrobenzenes; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation; Renal colic

Most Recent Events

  • 22 Oct 2002 No development reported - Preclinical for Renal colic in USA (unspecified route)
  • 21 Oct 2002 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
  • 25 Oct 2000 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top